<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46219">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504541</url>
  </required_header>
  <id_info>
    <org_study_id>QST-15-005</org_study_id>
    <nct_id>NCT02504541</nct_id>
  </id_info>
  <brief_title>Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism (STEADY)</brief_title>
  <acronym>STEADY</acronym>
  <official_title>A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antares Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antares Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of safety of a concentration controlled testosterone enanthate QuickShot
      Testosterone regimen administered subcutaneously once each week to adult males with
      hypogonadism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety assessments, including laboratory assessments, adverse events and injection site
      assessments, will be conducted for all patients at scheduled intervals during the Treatment
      Titration Period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events as a measure of Safety of QuickShot™ Testosterone (QST) administered subcutaneously (SC) once each week to adult males with hypogonadism</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Total Testosterone (TT) Ctrough values more than 300 ng/dL and less than or equal to 650 ng/dL at 12 weeks, 18 weeks and 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in follicle stimulating hormone (FSH) at end of Week 12 and Week 26</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in luteinizing hormone (LH) at end of Week 12 and Week 26</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sex hormone-binding globulin (SHBG) at end of Week 12 and Week 26</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) for testosterone enanthate (TE), TT and their metabolites dihydrotestosterone (DHT), dihydrotestosterone enanthate (DHTE) and estradiol (E2) for the 75 mg dose of QST at Week 1, Week 6 and Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average plasma concentration (Cavg) for TE, TT and their metabolites DHT, DHTE and E2 for the 75 mg dose of QST at Week 1, Week 6 and Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) for TE, TT and their metabolites DHT, DHTE and E2 for the 75 mg dose of QST at Week 1, Week 6 and Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Testosterone enanthate auto-injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone enanthate administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study. Three dose strengths are available: 100 mg, 75 mg, and 50 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone enanthate auto-injector</intervention_name>
    <description>Dose Adjustment 100 mg / 75 mg / 50 mg</description>
    <arm_group_label>Testosterone enanthate auto-injector</arm_group_label>
    <other_name>Testosterone</other_name>
    <other_name>Testosterone enanthate</other_name>
    <other_name>QuickShot® Testosterone (QST)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men ≥18 and ≤75 years of age with a documented history of hypogonadism

          -  Total testosterone levels &lt; 300 ng/dL at two qualification visits

          -  Patients in good general health

        Exclusion Criteria:

          -  Allergy to sesame or testosterone products

          -  BMI ≥ 40 kg/m2

          -  Hematocrit ≥ 52%

          -  History or current evidence of breast or prostate cancer

          -  Elevated prostate-specific antigen (PSA) for age.

          -  Abnormal digital rectal examination (DRE)

          -  Unstable psychiatric illnesses

          -  Obstructive uropathy of prostatic origin

          -  Poorly controlled diabetes

          -  Congestive heart failure

          -  Within 6 months of screening, myocardial infarction (MI), unstable angina leading to
             hospitalization, percutaneous coronary intervention, coronary artery bypass graft,
             uncontrolled cardiac arrhythmia, stroke transient ischemia attack, carotid
             revascularization, endovascular procedure, or surgical intervention for peripheral
             vascular disease.

          -  History or current treatment of thromboembolic disease.

          -  Use of adrenocorticotropic hormone (ACTH) or oral/depot corticosteroids within 6
             weeks of screening.

          -  History of severe, untreated sleep apnea

          -  Subjects with any clinically significant medical condition which, in the opinion of
             the investigator, would make the subject an unsuitable candidate for enrollment in
             the study

          -  Positive serology for HIV, hepatitis B or hepatitis C

          -  Current evidence of drug or alcohol abuse.

          -  Skin conditions in injection site that could confound injection site assessments.

          -  Administration of other investigational compounds within one month of screening or 5
             half-lives of the investigational compound, whichever is longer).

          -  Use of estrogen, gonadotropin-releasing hormone (GnRH) or growth hormone within 12
             months of screening.

          -  Use of other androgens (DHEA), anabolic steroids, other sex hormones) or other
             substances/supplements know to affect the pharmacokinetics (PK) of testosterone
             enanthate

          -  Considered or scheduled surgical or dental procedures associated with blood loss ≥500
             mL during study.

          -  Donation of plasma or blood within 56 days of screening or history of donation of &gt;
             50 mL of blood or plasma within 3 months of screening.

          -  Donation of plasma or blood during study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Bedel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prestige Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Valley City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 16, 2016</lastchanged_date>
  <firstreceived_date>July 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypogonadism</keyword>
  <keyword>Testosterone enanthate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
